X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Cadila Healthcare with MYLAN INC. - US - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CADILA HEALTHCARE vs MYLAN (US) - Comparison Results

CADILA HEALTHCARE    Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

MYLAN (US)
   Change

Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 CADILA HEALTHCARE   MYLAN
EQUITY SHARE DATA
    CADILA HEALTHCARE
Mar-18
MYLAN
Dec-14
CADILA HEALTHCARE/
MYLAN
5-Yr Chart
Click to enlarge
High Rs5584,238-   
Low Rs3622,986-   
Sales per share (Unadj.) Rs116.31,450.7-  
Earnings per share (Unadj.) Rs17.9174.8-  
Cash flow per share (Unadj.) Rs23.1281.3-  
Dividends per share (Unadj.) Rs3.500-  
Dividend yield (eoy) %0.80-  
Book value per share (Unadj.) Rs85.4721.1-  
Shares outstanding (eoy) m1,023.74378.37-   
Bonus/Rights/Conversions -OI-  
Price / Sales ratio x4.02.5 158.8%   
Avg P/E ratio x25.720.7 124.5%  
P/CF ratio (eoy) x19.912.8 154.8%  
Price / Book Value ratio x5.45.0 107.5%  
Dividend payout %19.60-   
Avg Mkt Cap Rs m470,6641,366,627 34.4%   
No. of employees `00011.825.0 47.3%   
Total wages/salary Rs m18,5450-   
Avg. sales/employee Rs Th10,072.721,955.7 45.9%   
Avg. wages/employee Rs Th1,569.10-   
Avg. net profit/employee Rs Th1,547.72,644.9 58.5%   
INCOME DATA
Net Sales Rs m119,049548,892 21.7%  
Other income Rs m1,132-3,200 -35.4%   
Total revenues Rs m120,181545,693 22.0%   
Gross profit Rs m28,475136,512 20.9%  
Depreciation Rs m5,38840,314 13.4%   
Interest Rs m91123,676 3.8%   
Profit before tax Rs m23,30869,323 33.6%   
Minority Interest Rs m628-284 -220.8%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m5,6442,915 193.6%   
Profit after tax Rs m18,29266,123 27.7%  
Gross profit margin %23.924.9 96.2%  
Effective tax rate %24.24.2 575.8%   
Net profit margin %15.412.0 127.5%  
BALANCE SHEET DATA
Current assets Rs m82,005482,549 17.0%   
Current liabilities Rs m60,720377,257 16.1%   
Net working cap to sales %17.919.2 93.2%  
Current ratio x1.41.3 105.6%  
Inventory Days Days7378 93.7%  
Debtors Days Days98107 91.6%  
Net fixed assets Rs m83,703126,985 65.9%   
Share capital Rs m1,02419,410 5.3%   
"Free" reserves Rs m86,4210-   
Net worth Rs m87,445272,853 32.0%   
Long term debt Rs m25,551407,616 6.3%   
Total assets Rs m180,6531,099,028 16.4%  
Interest coverage x26.63.9 676.8%   
Debt to equity ratio x0.31.5 19.6%  
Sales to assets ratio x0.70.5 131.9%   
Return on assets %10.68.2 130.1%  
Return on equity %20.924.2 86.3%  
Return on capital %22.013.6 161.4%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m31,4410-   
CASH FLOW
From Operations Rs m9,19372,152 12.7%  
From Investments Rs m-9,737-56,901 17.1%  
From Financial Activity Rs m515-19,012 -2.7%  
Net Cashflow Rs m-29-3,761 0.8%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 71.1 Rs / USD

Compare CADILA HEALTHCARE With: ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  

Compare CADILA HEALTHCARE With: STRIDES PHARMA SCIENCE  ABBOTT INDIA  FDC LTD.  NOVARTIS  SUN PHARMA  



Today's Market

Recapitalisation Package for PSBs: The Pros & Cons(Podcast)

Corporate governance issues with certain companies, uncertainty surrounding national elections and global issues like trade wars, Brexit, have taken a toll on the Indian markets.

Related Views On News

CADILA HEALTHCARE Announces Quarterly Results (3QFY19); Net Profit Down 3.7% (Quarterly Result Update)

Feb 12, 2019 | Updated on Feb 12, 2019

For the quarter ended December 2018, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (down 3.7% YoY). Sales on the other hand came in at Rs 36 bn (up 9.8% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

CADILA HEALTHCARE Announces Quarterly Results (2QFY19); Net Profit Down 18.6% (Quarterly Result Update)

Nov 5, 2018 | Updated on Nov 5, 2018

For the quarter ended September 2018, CADILA HEALTHCARE has posted a net profit of Rs 4 bn (down 18.6% YoY). Sales on the other hand came in at Rs 30 bn (down 8.4% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

CADILA HEALTHCARE 2017-18 Annual Report Analysis (Annual Result Update)

Aug 16, 2018 | Updated on Aug 16, 2018

Here's an analysis of the annual report of CADILA HEALTHCARE for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of CADILA HEALTHCARE. Also includes updates on the valuation of CADILA HEALTHCARE.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

The One Real Estate Stock to Buy Now(The 5 Minute Wrapup)

Feb 13, 2019

The real estate sector is ready to make a comeback. This is the stock to consider buying.

Don't Be Afraid of the Market; Buy Stocks Like This One(The 5 Minute Wrapup)

Feb 14, 2019

During this tough period in the market, a contrarian approach holds huge potential upside for this Smart Money Secrets stock.

Small Caps Under Seige: Could This Be A Once-in-a-Decade Wealth Creating Opportunity?(Profit Hunter)

Feb 14, 2019

Don't let the dark clouds hovering over small caps scare you into hiding; it will rain gold as sentiments recover. Indeed, there is a blood bath. And if you are a first time investor, the correction is deep enough to scare you out of markets.

The 4-Point Plan to Accelerate India to a 10 Trillion Dollar Economy(The 5 Minute Wrapup)

Feb 12, 2019

Two questions I have been eagerly waiting to ask you ever since Budget 2019 was announced.

The Train to 'Small-Cap-Profits Land' is Back on the Station!(Profit Hunter)

Feb 15, 2019

Why its great news that prices for small caps over the last few days have been falling like there's no tomorrow.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

CADILA HEALTHCARE SHARE PRICE


Feb 22, 2019 (Close)

TRACK CADILA HEALTHCARE

  • Track your investment in CADILA HEALTHCARE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON CADILA HEALTHCARE

CADILA HEALTHCARE 5-YR ANALYSIS

COMPARE CADILA HEALTHCARE WITH

MARKET STATS